SCHEMBL16164427

SCHEMBL16164427

NC(=O)c1cc(F)c(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 13/20 0.59
▸ FER P16591 5/20 0.52
▸ CAMK1D Q8IU85 2/20 0.49
▸ JAK2 O60674 1/20 0.47
▸ ROCK2 O75116 1/20 0.47
▸ MAP4K4 O95819 1/20 0.47
▸ HCK P08631 1/20 0.47
▸ ROS1 P08922 1/20 0.47
▸ PIM1 P11309 1/20 0.47
▸ PRKACA P17612 1/20 0.47
▸ MARK3 P27448 1/20 0.47
▸ LTK P29376 1/20 0.47
▸ FLT3 P36888 1/20 0.47
▸ CSNK1A1 P48729 1/20 0.47
▸ CLK2 P49760 1/20 0.47
▸ MAPK10 P53779 1/20 0.47
▸ MAP2K1 Q02750 1/20 0.47
▸ MAP3K10 Q02779 1/20 0.47
▸ PRKCQ Q04759 1/20 0.47
▸ PTK2 Q05397 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14909384 0.91 SYK (0.53) SYKFER
SCHEMBL14910838 0.91 FER (0.61) SYKFERCAMK1DJAK2ROCK2
SCHEMBL14909381 0.91 SYK (0.53) SYKFER
SCHEMBL14929774 0.91 FER (0.61) SYKFERCAMK1DJAK2ROCK2
SCHEMBL14910837 0.91 FER (0.61) SYKFERCAMK1DJAK2ROCK2
SCHEMBL16165042 0.89 SYK (0.47) SYKFERCAMK1D
SCHEMBL18925650 0.88 SYK (0.58) SYKFERCAMK1DJAK2ROCK2
SCHEMBL5027999 0.88 SYK (0.58) SYKFERCAMK1DJAK2ROCK2
SCHEMBL14929115 0.87 FER (0.65) SYKFER
SCHEMBL14909740 0.87 FER (0.65) SYKFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2799431-B1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORP (JP) 2018-01-24 — — EP disclosed
US-9051310-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2015-06-09 — — US disclosed
EP-2799431-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM Corporation (JP) 2014-11-05 — — EP disclosed
US-20140309225-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2014-10-16 — — US disclosed
US-20140309225-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2014-10-16 — — US disclosed
US-20140309225-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2014-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309225-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, BTK, NOX4 SYK 1/4885FER 441/4885CAMK1D 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback